Atika Capital Management LLC
Q1 2014 13F-HR Holdings
Net value change ($000)
+5,015
(4.5%)
New positions
13
Sold out positions
20
Turnover %
47.0%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q4 2013
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| INTERCEPT PHARMACEUTICALS, INC. | 3,182 | 245.3% |
| BIIB | 2,600 | NEW |
| Endo International plc | 2,367 | NEW |
| INCY | 2,195 | 154.8% |
| INSYS THERAPEUTICS INC | 2,064 | NEW |
| SOLARCITY CORP | 2,006 | 357.6% |
| EHTH | 2,004 | 47.5% |
| LVS | 1,979 | NEW |
| MLM | 1,925 | NEW |
| EXP | 1,745 | 60.9% |
Top Reduces (Value $000, Stocks/ETFs)
| GILD | -3,913 | -100.0% |
| CONTAINER STORE GROUP INC | -3,004 | -100.0% |
| MEDIA GENERAL INC | -2,882 | -100.0% |
| GENTIUM SPA SPONSORED ADR | -2,627 | -100.0% |
| LINKEDIN CORP | -2,494 | -100.0% |
| NFLX | -2,258 | -68.1% |
| JAZZ | -2,107 | -100.0% |
| MEDIVATION | -2,106 | -100.0% |
| ENDO PHARMACEUTICALS HLDGS | -2,034 | -100.0% |
| OMNICARE | -1,715 | -43.7% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
11,671
(9.9% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|